X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (194559) 194559
Magazine Article (309) 309
Book / eBook (255) 255
Newsletter (118) 118
Book Chapter (96) 96
Newspaper Article (95) 95
Government Document (85) 85
Conference Proceeding (76) 76
Dissertation (52) 52
Web Resource (49) 49
Publication (28) 28
Book Review (9) 9
Reference (5) 5
Journal / eJournal (3) 3
Paper (2) 2
Trade Publication Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (182430) 182430
female (148357) 148357
breast neoplasms - pathology (104107) 104107
oncology (81205) 81205
middle aged (74507) 74507
breast cancer (70171) 70171
adult (58075) 58075
aged (56952) 56952
cancer (48392) 48392
breast-cancer (34103) 34103
animals (33981) 33981
prognosis (33531) 33531
male (31152) 31152
cell line, tumor (28584) 28584
breast neoplasms - metabolism (27248) 27248
metastasis (26224) 26224
breast neoplasms - genetics (25565) 25565
expression (24591) 24591
breast neoplasms - drug therapy (24231) 24231
tumors (23581) 23581
aged, 80 and over (22857) 22857
neoplasm staging (22035) 22035
mice (21924) 21924
immunohistochemistry (21411) 21411
pathology (20566) 20566
carcinoma (19634) 19634
research (19241) 19241
breast neoplasms - surgery (18911) 18911
surgery (18345) 18345
chemotherapy (16801) 16801
cell biology (15847) 15847
analysis (15692) 15692
gene expression regulation, neoplastic (14804) 14804
retrospective studies (14800) 14800
breast neoplasms - diagnosis (14669) 14669
care and treatment (14613) 14613
apoptosis (14609) 14609
survival (14564) 14564
medicine & public health (14323) 14323
gene expression (14245) 14245
breast (13797) 13797
risk factors (13717) 13717
lymphatic metastasis (13291) 13291
treatment outcome (12953) 12953
health aspects (12759) 12759
neoplasm metastasis (12333) 12333
diagnosis (11978) 11978
genetic aspects (11705) 11705
breast neoplasms - mortality (11639) 11639
proteins (11299) 11299
research article (11180) 11180
neoplasm invasiveness (11161) 11161
biochemistry & molecular biology (11086) 11086
biopsy (11005) 11005
breast - pathology (10821) 10821
follow-up studies (10721) 10721
mammography (10454) 10454
breast neoplasms - diagnostic imaging (10345) 10345
therapy (10225) 10225
breast neoplasms - therapy (10080) 10080
women (10032) 10032
tumor cells, cultured (9981) 9981
cells (9688) 9688
medicine (9505) 9505
radiology, nuclear medicine & medical imaging (9491) 9491
cell proliferation (9469) 9469
development and progression (9440) 9440
growth (9205) 9205
signal transduction (9078) 9078
risk (8842) 8842
neoplasms - pathology (8785) 8785
carcinoma, ductal, breast - pathology (8620) 8620
metastases (8506) 8506
survival analysis (8425) 8425
antineoplastic combined chemotherapy protocols - therapeutic use (8272) 8272
mutation (8210) 8210
disease-free survival (8083) 8083
time factors (8073) 8073
survival rate (7889) 7889
mastectomy (7786) 7786
cancer therapies (7747) 7747
biomarkers, tumor - metabolism (7609) 7609
mice, nude (7599) 7599
disease progression (7388) 7388
multidisciplinary sciences (7292) 7292
cancer research (7285) 7285
lymph nodes - pathology (7224) 7224
antineoplastic agents - pharmacology (7201) 7201
medical prognosis (7153) 7153
sensitivity and specificity (7135) 7135
patients (7028) 7028
antineoplastic agents - therapeutic use (7004) 7004
cell proliferation - drug effects (6973) 6973
apoptosis - drug effects (6873) 6873
genes (6760) 6760
studies (6627) 6627
oncology, experimental (6568) 6568
obstetrics & gynecology (6507) 6507
proliferation (6487) 6487
prospective studies (6448) 6448
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (117) 117
Online Resources - Online (49) 49
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (20) 20
Collection Dvlpm't (Acquisitions) - Vendor file (15) 15
Collection Dvlpm't (Acquisitions) - Closed Orders (13) 13
Gerstein Science - Circulation Desk (4) 4
Humber River Regional Hospital - Church Stacks (4) 4
Mt Sinai Hospital - Pathology (4) 4
Women's College Hospital - Stacks (4) 4
Humber River Regional Hospital - Finch Stacks (3) 3
Markham Stouffville Hospital - Stacks (3) 3
New College (Ivey) - Stacks (3) 3
Scarborough Hospital - General (3) 3
Scarborough Hospital - Online (3) 3
St. Michael's Hospital - Stacks (3) 3
UofT at Scarborough - Stacks (2) 2
Women's College Hospital - Online (2) 2
Holland Bloorview Kids Rehabilitation - Stacks (1) 1
Humber River Regional Hospital - Finch Reference (1) 1
Lakeridge Health Sciences - Online (1) 1
Lakeridge Health Sciences - Oshawa (1) 1
Providence Healthcare - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
St. Michael's Hospital - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Patient Education (1) 1
Thomas Fisher Rare Book - Rare Book (1) 1
Toronto East General Hospital - Reference (1) 1
UofT at Mississauga - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (184973) 184973
German (2506) 2506
Japanese (2340) 2340
French (2306) 2306
Chinese (1757) 1757
Russian (1073) 1073
Italian (951) 951
Spanish (702) 702
Polish (246) 246
Hungarian (211) 211
Dutch (189) 189
Portuguese (175) 175
Czech (152) 152
Danish (118) 118
Romanian (73) 73
Hebrew (70) 70
Bulgarian (68) 68
Norwegian (66) 66
Croatian (46) 46
Serbian (36) 36
Korean (31) 31
Swedish (31) 31
Ukrainian (26) 26
Finnish (23) 23
Turkish (23) 23
Slovak (20) 20
Arabic (8) 8
Bosnian (5) 5
Afrikaans (3) 3
Latvian (3) 3
Lithuanian (3) 3
Persian (3) 3
Greek (2) 2
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature cell biology, ISSN 1476-4679, 2018, Volume 20, Issue 8, pp. 954 - 965
BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To... 
PATHWAY CHOICE | STRAND BREAK REPAIR | RESECTION | DAMAGE-RESPONSE | 53BP1 | CLASS-SWITCH RECOMBINATION | FANCONI-ANEMIA | DIFFERENTIAL EXPRESSION ANALYSIS | POLYMERASE-ZETA | TELOMERES | CELL BIOLOGY | Osteosarcoma - drug therapy | Mad2 Proteins - metabolism | Humans | Multiprotein Complexes | Ovarian Neoplasms - pathology | Bone Neoplasms - pathology | DNA Breaks, Double-Stranded | Bone Neoplasms - metabolism | Breast Neoplasms - metabolism | Dose-Response Relationship, Drug | Ovarian Neoplasms - genetics | Telomere-Binding Proteins - genetics | DNA End-Joining Repair | HEK293 Cells | Female | Bone Neoplasms - genetics | Ovarian Neoplasms - metabolism | Bone Neoplasms - drug therapy | BRCA1 Protein - deficiency | Telomere-Binding Proteins - metabolism | Ovarian Neoplasms - drug therapy | Osteosarcoma - metabolism | DNA-Binding Proteins | Tumor Suppressor p53-Binding Protein 1 - metabolism | Recombinational DNA Repair | Tumor Suppressor p53-Binding Protein 1 - genetics | Cisplatin - pharmacology | Breast Neoplasms - drug therapy | Proteins - genetics | Xenograft Model Antitumor Assays | BRCA1 Protein - genetics | Poly(ADP-ribose) Polymerase Inhibitors - pharmacology | Drug Resistance, Neoplasm - genetics | Animals | Breast Neoplasms - genetics | Proteins - metabolism | Breast Neoplasms - pathology | Mad2 Proteins - genetics | Cell Line, Tumor | Mice | Osteosarcoma - genetics | Cell Cycle Proteins | Osteosarcoma - pathology | Care and treatment | DNA | Cancer cells | Breast cancer | Genetic aspects | Research | Gene expression | Single-stranded DNA | DNA damage | Homologous recombination | Poly(ADP-ribose) | Homology | Genomes | Inactivation | Proteins | Ribose | Null cells | Deoxyribonucleic acid--DNA | BRCA2 protein | CRISPR | Deactivation | BRCA1 protein | Poly(ADP-ribose) polymerase | Adenosine diphosphate | Oligosaccharides | Double-strand break repair | Screens | Cisplatin | Polymerase | Inhibitors | Prostate | Viability | Tumors | Telomere-Binding Proteins / metabolism | Osteosarcoma / genetics | Telomere-Binding Proteins / genetics | BRCA1 Protein / genetics | Cellular Biology | Genetics | Proteins / genetics | Osteosarcoma / drug therapy | Ovarian Neoplasms / genetics | Mad2 Proteins / genetics | Proteins / metabolism | Breast Neoplasms / drug therapy | Breast Neoplasms / metabolism | Tumor Suppressor p53-Binding Protein 1 / genetics | BRCA1 Protein / deficiency | Ovarian Neoplasms / metabolism | Mad2 Proteins / metabolism | Breast Neoplasms / pathology | Bone Neoplasms / genetics | Ovarian Neoplasms / pathology | Bone Neoplasms / pathology | Life Sciences | Bone Neoplasms / drug therapy | Ovarian Neoplasms / drug therapy | Osteosarcoma / metabolism | Biochemistry, Molecular Biology | Breast Neoplasms / genetics | Drug Resistance, Neoplasm / genetics | Osteosarcoma / pathology | Bone Neoplasms / metabolism | Poly(ADP-ribose) Polymerase Inhibitors / pharmacology | Cisplatin / pharmacology | Molecular biology | Tumor Suppressor p53-Binding Protein 1 / metabolism | Cancer
Journal Article
CA: a cancer journal for clinicians, ISSN 0007-9235, 2016, Volume 66, Issue 5, pp. 408 - 436
... when most invasive cancers in most anatomic sites might be prevented with similar interventions. This review, amassed with the collective expertise of pathology colleagues... 
carcinoma in situ | dysplasia | intraepithelial neoplasia | preinvasive neoplasia | precancer | HIGH-GRADE DYSPLASIA | URINARY-BLADDER | BARRETTS-ESOPHAGUS | HUMAN-PAPILLOMAVIRUS | INTRADUCTAL CARCINOMA | CARCINOMA IN-SITU | PAPILLARY UROTHELIAL HYPERPLASIA | ONCOLOGY | SINGLE ACADEMIC CENTER | TERM-FOLLOW-UP | NECK-CANCER IMPLICATIONS | Humans | Lung Neoplasms - metabolism | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Male | Uterine Cervical Neoplasms - pathology | Head and Neck Neoplasms - metabolism | Breast Neoplasms - metabolism | Esophageal Neoplasms - pathology | Breast Neoplasms - therapy | American Cancer Society | Uterine Cervical Neoplasms - metabolism | Skin Neoplasms - diagnosis | Urinary Bladder Neoplasms - pathology | Female | Ovarian Neoplasms - metabolism | Uterine Cervical Neoplasms - therapy | Skin Neoplasms - pathology | Prostatic Neoplasms - pathology | Uterine Cervical Neoplasms - diagnosis | Skin Neoplasms - therapy | Carcinoma in Situ - pathology | Ovarian Neoplasms - diagnosis | Pancreatic Neoplasms - pathology | Risk Factors | Head and Neck Neoplasms - therapy | Lung Neoplasms - therapy | Carcinoma in Situ - therapy | Head and Neck Neoplasms - pathology | Skin Neoplasms - metabolism | Breast Neoplasms - pathology | Ovarian Neoplasms - therapy | Head and Neck Neoplasms - diagnosis | Breast Neoplasms - diagnosis | Carcinoma in Situ - diagnosis | Carcinoma in Situ - metabolism | Lung Neoplasms - diagnosis | Population Surveillance | Prevention | Care and treatment | Gastrointestinal system | Practice | Pathologists | Metastasis | Patients | Health aspects | Cervical cancer | Risk factors | Pathology | Usage | Diagnosis | Tumors | Medical diagnosis | Cancer
Journal Article
Seminars in Oncology, ISSN 0093-7754, 2015, Volume 42, Issue 6, pp. 801 - 819
The fibroblast growth factor receptor (FGFR) pathway plays a major role in several biological processes, from organogenesis to metabolism homeostasis and... 
BREAST-CANCER | LUNG-CANCER | IN-VITRO | ONCOLOGY | SQUAMOUS-CELL CARCINOMA | RESISTANCE | GENE AMPLIFICATION | POTENTIAL THERAPEUTIC TARGET | PROGNOSTIC-SIGNIFICANCE | ANTITUMOR-ACTIVITY | EXPRESSION | Neoplasms - metabolism | Gastrointestinal Neoplasms - genetics | Gastrointestinal Neoplasms - drug therapy | Humans | Brain Neoplasms - pathology | Fibroblast Growth Factors - genetics | Brain Neoplasms - metabolism | Head and Neck Neoplasms - metabolism | Breast Neoplasms - metabolism | Fibroblast Growth Factors - metabolism | Gastrointestinal Neoplasms - pathology | Glioblastoma - genetics | Receptors, Fibroblast Growth Factor - genetics | Female | Glioblastoma - metabolism | Antineoplastic Agents - pharmacology | Molecular Targeted Therapy - methods | Gastrointestinal Neoplasms - metabolism | Biomarkers, Tumor - analysis | Head and Neck Neoplasms - drug therapy | Receptors, Fibroblast Growth Factor - antagonists & inhibitors | Thoracic Neoplasms - pathology | Brain Neoplasms - genetics | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Thoracic Neoplasms - metabolism | Head and Neck Neoplasms - pathology | Neoplasms - drug therapy | Breast Neoplasms - genetics | Thoracic Neoplasms - genetics | Breast Neoplasms - pathology | Glioblastoma - pathology | Receptors, Fibroblast Growth Factor - metabolism | Head and Neck Neoplasms - genetics | Fibroblast Growth Factors - antagonists & inhibitors | Thoracic Neoplasms - drug therapy | Glioblastoma - drug therapy | Neoplasms - pathology | Drug Resistance, Neoplasm - physiology | Drug Resistance, Neoplasm - drug effects | Index Medicus
Journal Article
Cancer causes & control, ISSN 1573-7225, 2008, Volume 20, Issue 4, pp. 417 - 435
Background Population-based cancer registry data from the Surveillance, Epidemiology, and End Results (SEER) Program at the National Cancer Institute (NCI) are... 
Socioeconomic status | Prophets | Mortality | Censuses | Cancer incidence | Breast cancer | Socioeconomics | Educational attainment | Lung neoplasms | Cancer | NLMS | SES | Poverty | Hematology | Rural/urban | Income | Oncology | Record linkage | Public Health/Gesundheitswesen | Epidemiology | Unemployment | Biomedicine general | Biomedicine | Education | Race/ethnicity | Cancer Research | SEER | Stage | Health disparities | RACIAL-DIFFERENCES | BREAST-CANCER | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | PROSTATE-CANCER | UNITED-STATES | CERVICAL-CANCER | RESULTS PROGRAM | US WOMEN | SOCIAL-CLASS | DEATH INDEX | ONCOLOGY | COLORECTAL-CANCER | Melanoma - epidemiology | Lung Neoplasms - ethnology | United States - epidemiology | Uterine Cervical Neoplasms - ethnology | Lung Neoplasms - mortality | Humans | Survivors - statistics & numerical data | Uterine Cervical Neoplasms - epidemiology | Lung Neoplasms - pathology | Male | Uterine Cervical Neoplasms - pathology | Incidence | Neoplasms - ethnology | Female | Registries | Medical Record Linkage | Breast Neoplasms - ethnology | Uterine Cervical Neoplasms - mortality | Breast Neoplasms - epidemiology | Ethnic Groups - statistics & numerical data | Prostatic Neoplasms - pathology | SEER Program | Melanoma - ethnology | Neoplasms - mortality | Prostatic Neoplasms - ethnology | Melanoma - pathology | Prostatic Neoplasms - mortality | Social Class | Prostatic Neoplasms - epidemiology | Lung Neoplasms - epidemiology | Breast Neoplasms - pathology | Healthcare Disparities | Breast Neoplasms - mortality | Neoplasm Staging | Neoplasms - pathology | Longitudinal Studies | Neoplasms - epidemiology | Cohort Studies | Melanoma - mortality | Social classes | Usage | Demographic aspects | Social aspects | Health aspects | Epidemiologic methods | Rural | ethnicity | Original Paper | urban | Race
Journal Article
The lancet oncology, ISSN 1470-2045, 2017, Volume 18, Issue 1, pp. 75 - 87
Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1... 
Hematology, Oncology and Palliative Medicine | POLY(ADP-RIBOSE) POLYMERASE | OLAPARIB | ONCOLOGY | HOMOLOGOUS RECOMBINATION DEFICIENCY | MUTANT-CELLS | DNA-REPAIR | CANCER | HETEROZYGOSITY | TUMORS | BREAST | GENOMIC LOSS | Prognosis | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Salvage Therapy | Neoplasm Recurrence, Local - drug therapy | Germ-Line Mutation - genetics | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasms, Glandular and Epithelial - genetics | Peritoneal Neoplasms - drug therapy | Fallopian Tube Neoplasms - genetics | Female | Antineoplastic Agents - pharmacology | Poly(ADP-ribose) Polymerases - chemistry | Ovarian Neoplasms - drug therapy | Platinum - pharmacology | Fallopian Tube Neoplasms - drug therapy | Peritoneal Neoplasms - pathology | Neoplasms, Glandular and Epithelial - pathology | Fallopian Tube Neoplasms - pathology | Survival Rate | Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use | BRCA1 Protein - genetics | International Agencies | Peritoneal Neoplasms - genetics | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Indoles - therapeutic use | Neoplasm Recurrence, Local - genetics | Aged | Neoplasm Staging | BRCA2 Protein - genetics | Drug Resistance, Neoplasm - drug effects | Sugars | Monosaccharides | Ovarian cancer | Analysis | Carcinoma | Cancer
Journal Article
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 2012, Volume 83, Issue 3, pp. 878 - 886
Purpose To analyze the long-term survival and tumor control outcomes after stereotactic body radiotherapy (SBRT) for metastases limited in number and extent.... 
Radiology | Hematology, Oncology and Palliative Medicine | Stereotactic body radiotherapy | Breast cancer | Oligometastases | Survival | Metastases | ACR PRACTICE GUIDELINES | PHASE I/II TRIAL | HEPATIC RESECTION | CELL LUNG-CANCER | LIVER METASTASES | ONCOLOGY ASTRO | ONCOLOGY | COLORECTAL-CANCER | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | AMERICAN SOCIETY | RADIATION-THERAPY SBRT | TUMOR VOLUME | Bone Neoplasms - mortality | Sarcoma - secondary | Prospective Studies | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Bone Neoplasms - secondary | Carcinoma, Squamous Cell - surgery | Liver Neoplasms - mortality | Radiosurgery - adverse effects | Brain Neoplasms - surgery | Esophageal Neoplasms - pathology | Brain Neoplasms - secondary | Carcinoma, Squamous Cell - mortality | Lung Neoplasms - secondary | Sarcoma - mortality | Aged, 80 and over | Adult | Female | Brain Neoplasms - mortality | Liver Neoplasms - secondary | Radiosurgery - methods | Colorectal Neoplasms - mortality | Neoplasm Metastasis - radiotherapy | Liver Neoplasms - surgery | Lymphatic Metastasis | Bone Neoplasms - surgery | Adenocarcinoma - secondary | Head and Neck Neoplasms - pathology | Breast Neoplasms - pathology | Sarcoma - surgery | Breast Neoplasms - mortality | Carcinoma, Squamous Cell - secondary | Lung Neoplasms - surgery | Aged | Head and Neck Neoplasms - mortality | Colorectal Neoplasms - pathology | Adenocarcinoma - mortality | Adenocarcinoma - surgery | Radiotherapy | Nuclear radiation | Analysis | Radiation | MULTIVARIATE ANALYSIS | PATIENTS | MAMMARY GLANDS | NEOPLASMS | METASTASES | RADIOLOGY AND NUCLEAR MEDICINE | DEATH | REGRESSION ANALYSIS | RADIOTHERAPY | HAZARDS | SKELETON
Journal Article
Scientific reports, ISSN 2045-2322, 2017, Volume 7, Issue 1, pp. 15500 - 10
Journal Article
Human Pathology, ISSN 0046-8177, 2013, Volume 44, Issue 11, pp. 2563 - 2570
Summary BRAF mutation is seen in a variety of human neoplasms including cutaneous malignant melanoma, papillary thyroid carcinoma, colorectal carcinoma, non... 
Pathology | Immunohistochemistry | Anti–B-Raf | BRAF V600E | VE1 | Glioma | Melanoma | Thyroid carcinoma | Anti-B-Raf | PROTEIN | IMPROVED SURVIVAL | PATHOLOGY | CANCER | TUMORS | THERAPY | MEK INHIBITION | GENE | MUTANT BRAF | Neoplasms - metabolism | Gastrointestinal Neoplasms - genetics | Humans | Lung Neoplasms - metabolism | Ovarian Neoplasms - pathology | Lung Neoplasms - pathology | Mutation, Missense | Breast Neoplasms - metabolism | Glioma - metabolism | Glioma - genetics | Ovarian Neoplasms - genetics | Gastrointestinal Neoplasms - pathology | Neoplasms - genetics | DNA Mutational Analysis | Melanoma - genetics | Glioma - pathology | Sensitivity and Specificity | Biomarkers, Tumor - metabolism | Female | Ovarian Neoplasms - metabolism | Carcinoma - pathology | Antibodies, Monoclonal - immunology | Proto-Oncogene Proteins B-raf - metabolism | Gastrointestinal Neoplasms - metabolism | Lung Neoplasms - genetics | Melanoma - metabolism | Mutant Proteins - genetics | Mutant Proteins - metabolism | Melanoma - pathology | Thyroid Neoplasms - genetics | Breast Neoplasms - genetics | Breast Neoplasms - pathology | Proto-Oncogene Proteins B-raf - genetics | Carcinoma - genetics | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasms - pathology | Amino Acid Substitution | Thyroid Neoplasms - metabolism | Thyroid Neoplasms - pathology | Carcinoma | Gene mutations | Gliomas | Thyroid diseases | Monoclonal antibodies | Genetic aspects | Comparative analysis | Lung cancer, Non-small cell | Cancer | Breast cancer | Mutation | Tumors | Skin cancer
Journal Article